Progentec Diagnostics Awarded SBIR Fast-Track Grant to Develop Immune Mediator-Based Blood Tests for Clinical Disease Activity in Lupus (SLE)

Progentec, a leader in the development of technological innovations in the field of diagnostics, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID). The grant funds will be released in two installments starting with a Phase I award of $225,000. In total, the grant has the potential to provide $1.7 million in non-dilutive financial resources.

The grant supports clinical research to evaluate the accuracy and predictive power of blood biomarker-based laboratory tests for the measurement of SLE (Lupus) disease activity. Current measures of disease activity, including the SLE disease activity index 2000 (SLEDAI-2K), require clinician assessment and offer no forecasting potential. “We anticipate that the tests in development by Progentec will support clinicians in selecting optimal treatment plans, adjusting medication dosing, and measuring outcomes for lupus patients,” said Mohan Purushothaman, Ph.D., the CEO of Progentec.


Fundingportal helps organizations like yours to get funded >